Cardiovascular Benefits of Oral Appliance Therapy in Obstructive Sleep Apnea: A Systematic Review

Gilles Van Haesendonck, BSc1; Marijke Dieltjens, MBS2; Chloé Kastoer, MD2; Bharati Shivalkar, MD, PhD1,4; Christiaan Vrints, MD, PhD1,4; Caroline M. Van De Heyning, MD, PhD1,4; Marc J. Braem, DDS, PhD1,2; Olivier M. Vanderveken, MD, PhD1,3

1University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium; 2Antwerp University Hospital, Department of Special Care Dentistry, Edegem, Antwerp, Belgium; 3Antwerp University Hospital, Otolaryngology and Head and Neck Surgery, Edegem, Antwerp, Belgium; 4Antwerp University Hospital, Cardiology, Edegem, Antwerp, Belgium

OBJECTIVES: To perform a systematic review of the current evidence regarding the cardiovascular benefits of oral appliance (OA) therapy in obstructive sleep apnea (OSA) patients.

METHODS: A systematic review of relevant articles retrieved from online databases (PubMed, Web of Science, Medline, OvidSP) was conducted. All relevant studies published prior to January 20, 2013 that examined the effects of OA on any of the cardiovascular parameters were included.

RESULTS: OA therapy could have a beneficial effect on blood pressure (BP), endothelial function (EF), and left ventricular (LV) function of the heart. Eleven articles were included in this systematic review; 7 of 8 studies showed a significant reduction in BP with a mean BP decrease of 4.2 mm Hg, 2 studies showed significant improvement in EF, and 1 study showed significant improvement in LV heart function.

CONCLUSION: OA therapy showed beneficial effects on the cardiovascular comorbidity in OSA patients. In studies comparing OA to CPAP therapy, effects of OA therapy were in the same order of magnitude as the effect of CPAP therapy.

KEYWORDS: obstructive sleep apnea, cardiovascular, oral appliance therapy, blood pressure


Obstructive sleep apnea (OSA) is characterized by repetitive episodes of partial or total upper airway obstruction during sleep, resulting in a decrease of oronasal airflow.1 OSA is acknowledged as a serious health problem,2,3 and it is the most common sleep-related breathing disorder. The current prevalence estimates of moderate to severe sleep disordered breathing (apnea-hypopnea index [AHI], measured as events/hour, ≥ 15) are 10% among 30- to 49-year-old men, 17% among 50- to 70-year-old men, 3% among 30- to 49-year-old women, and 9% among 50- to 70-year-old women.4

The pathophysiology of OSA and its effect on cardiovascular conditions has been reviewed extensively.2,5,6 During an episode of upper airway obstruction, respiratory effort against the occluded airway generates a negative intrathoracic pressure that increases left ventricular transmural pressure. The increased stress on cardiac muscle stimulates autoregulatory mechanisms that lead to thickening of the left ventricular (LV) wall over time. Negative intrathoracic pressure also increases right ventricular pressure during diastole, and the apnea-induced hypoxia causes pulmonary vasoconstriction, increasing right ventricular afterload.7 Long-term intermittent hypoxia can induce oxidative stress and activate inflammatory pathways that impair vascular endothelial function (EF).8,9 The brief arousal from sleep that accompanies apnea termination increases sympathetic activity and suppresses vagal tone. These acute effects do not only lead to oscillations in blood pressure (BP) and heart rate during sleep, but these may also result in daytime hypertension, increased heart rate during the day, and congestive heart failure.10,11 Hypertension has been found in a large group of OSA patients, and a positive correlation between BP and OSA severity has been shown.12-14 The repetitive interruptions in breathing cause sleep fragmentation associated with hypoxia and provoke overnight hypertension, leading to atrial fibrillation (AF), myocardial infarction (MI) and sudden death.15

Continuous positive airway pressure (CPAP) is the gold standard treatment for OSA.16 However, despite its high therapeutic efficacy, CPAP is often not well tolerated by patients, resulting in low compliance rate and limited clinical effectiveness.17,18 Today, oral appliances, particularly mandibular advancement devices (OAm), are considered to be a valuable non-invasive treatment option for patients with sleep apnea and for patients who do not comply with or refuse CPAP treatment.19-23 They are worn intraorally at night in order to advance the mandible, thereby reducing the collapsibility of the upper airway.14,21,24 Studies have shown that OAm patients have been more compliant than CPAP patients. This higher compliance results in a comparable effectiveness.25-27

Gaining insight in pathophysiology and treatment of OSA becomes increasingly relevant, as OSA is a common disorder with a range of harmful sequelae. The estimated prevalence rates of OSA represent substantial increases (up to 55%) partly due to increasing awareness and the ongoing obesity epidemic.4 BP, EF, and LV function of the heart are frequently used to assess cardiovascular morbidity in association with OSA in literature.19 These objective parameters give an indication of cardiovascular changes during OAm therapy in comparison with baseline measurements, thus clarifying the possible beneficial effect of OAm therapy as an alternative for CPAP. Since the cardiovascular morbidity and mortality is an important feature
in OSA, we performed a systematic review of articles studying cardiovascular changes during OAm therapy to expose the value of OAm.

<table>
<thead>
<tr>
<th>Table 1—Overview of search terms.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Search terms</td>
</tr>
<tr>
<td>Obstructive Sleep Apnea AND oral appliance AND blood pressure</td>
</tr>
<tr>
<td>Obstructive Sleep Apnea AND oral appliance AND cardiovascular</td>
</tr>
<tr>
<td>Obstructive Sleep Apnea AND oral appliance AND cardiovascular benefit OR cardiovascular improvement OR cardiovascular impact</td>
</tr>
<tr>
<td>Obstructive Sleep Apnea AND mandibular advancement AND blood pressure</td>
</tr>
</tbody>
</table>

METHODS

We searched 4 online databases: Pubmed, Web of Science, Medline and OvidSP. All relevant studies published prior to January 20, 2013, that examined the effects of OAm on any of the cardiovascular parameters were included. Using the results produced by the search terms listed in Table 1, a first selection was made based on the content of the title and abstract.

A second selection was then based on the evaluation of the content of the manuscripts. Studies that investigated non-cardiovascular effects of OAm or studies that did not include any oral appliance arm were excluded. Figure 1 explains the search strategy in detail. Finally, a total of 11 studies could be included in the present review. Because the topic of this literature study is relatively new, no exclusions were made based on publication date; all studies were published after 2003.

Systematic Review

Apnea-Hypopnea Index (AHI)

One way to measure the outcome of OAm therapy is using the apnea-hypopnea index (AHI) that represents the number of apneas and hypopneas per hour of sleep. An obstructive apnea is defined as an interruption in nocturnal breathing ≥ 10 sec despite continued respiratory effort. Hypopneas are abnormal respiratory events lasting ≥ 10 sec with ≥ 30% reduction in thoracoabdominal movement or airflow, and with ≥ 4% oxygen desaturation. Therefore, several studies not only described the cardiovascular effect of OAm, but also the change in AHI after OAm therapy. Table 2 represents the mean AHI values of the different studies.

Blood Pressure (BP)

As previously mentioned, there is a positive correlation between BP and OSA severity expressed in terms of AHI. The following studies investigated the effect of OAm therapy on a decrease in BP values.

In a randomized clinical trial protocol, Gotsopoulos et al. examined the BP of 61 patients diagnosed with OSA (AHI ≥ 10/h) before and after 4 weeks of OAm treatment. The control group was treated with an OAm without mandibular protrusion. They found a significant reduction of 24-h diastolic blood pressure (DBP) after OAm therapy in comparison to the control group, mainly due to the effect of therapy on daytime DBP. Daytime BP values with OAm were significantly lower than those of the control group: systolic blood pressure (SBP) $-3.3 \pm 1.1$ mm Hg, DBP $-3.4 \pm 0.9$ mm Hg and mean arterial pressure (MAP) $-3.6 \pm 0.9$ mm Hg. The 24-h heart rate (HR) was reduced in comparison to the control group, which was caused by a daytime HR reduction of 4 ± 1 beats per minute in comparison to the control group. The BP reduction after OAm therapy was most pronounced in the early morning, when the risk of a myocardial infarction is highest.

Barnes et al. examined 114 patients with mild to moderate OSA (5/h < AHI ≤ 30/h). In this RCT, patients were treated with CPAP, OAm, and placebo for 3 months each. Eighty patients completed all 3 treatments. Patients treated with OAm showed a significant decrease in DBP at night ($-2.2 \pm 0.7$ mm Hg). A significant number of the patients who did not show a BP dip at
Table 2—Summary of OAm treatment studies assessing blood pressure parameters.

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>N</th>
<th>Age (mean ± SD)</th>
<th>% Male (N)</th>
<th>BMI (mean ± SD)</th>
<th>Duration of intervention</th>
<th>Method of BP measurement</th>
<th>Mean SBP change (mm Hg)</th>
<th>Study Type</th>
<th>Pre AHI/h (mean ± SD)</th>
<th>Post AHI/h (mean ± SD)</th>
<th>Δ%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gotsopoulos et al.</td>
<td>2003</td>
<td>61</td>
<td>48 ± 11</td>
<td>79% (53)</td>
<td>28 ± 5</td>
<td>4 weeks</td>
<td>24-h</td>
<td>−3</td>
<td>RCT</td>
<td>28 ± 17</td>
<td>12 ± 2</td>
<td>57%</td>
</tr>
<tr>
<td>Barnes et al.</td>
<td>2004</td>
<td>114</td>
<td>46</td>
<td>79% (67)</td>
<td>31</td>
<td>12 weeks</td>
<td>24-h</td>
<td>0</td>
<td>RCT</td>
<td>21 ± 11</td>
<td>14 ± 10</td>
<td>34%</td>
</tr>
<tr>
<td>Yoshida et al.</td>
<td>2005</td>
<td>161</td>
<td>54 ± 14</td>
<td>75% (121)</td>
<td>25 ± 4</td>
<td>15 weeks</td>
<td>Clinical</td>
<td>−5</td>
<td>case series</td>
<td>18 ± 14</td>
<td>6 ± 6</td>
<td>68%</td>
</tr>
<tr>
<td>Otsuka et al.</td>
<td>2006</td>
<td>11</td>
<td>52 ± 7</td>
<td>73% (8)</td>
<td>29 ± 4</td>
<td>32 weeks</td>
<td>20-h</td>
<td>−5</td>
<td>case series</td>
<td>25 ± 20</td>
<td>6 ± 4</td>
<td>75%</td>
</tr>
<tr>
<td>Andrén et al.</td>
<td>2009</td>
<td>29</td>
<td>57</td>
<td>62% (18)</td>
<td>29 ± 4</td>
<td>3 years</td>
<td>Clinical</td>
<td>−14</td>
<td>case series</td>
<td>16 ± 9</td>
<td>4 ± 3</td>
<td>75%</td>
</tr>
<tr>
<td>Andrén et al.</td>
<td>2013</td>
<td>32</td>
<td>56 ± 8</td>
<td>79% (57)</td>
<td>29 ± 4</td>
<td>3 months</td>
<td>24-h</td>
<td>−2</td>
<td>RCT</td>
<td>23 ± 16</td>
<td>8 ± 6</td>
<td>66%</td>
</tr>
<tr>
<td>Lam et al.</td>
<td>2007</td>
<td>14</td>
<td>45</td>
<td>76% (26)</td>
<td>27</td>
<td>10 weeks</td>
<td>Clinical</td>
<td>−1</td>
<td>case series</td>
<td>21 ± 10</td>
<td>11 ± 10</td>
<td>49%</td>
</tr>
<tr>
<td>Phillips et al.</td>
<td>2010</td>
<td>49</td>
<td>49 ± 11</td>
<td>81% (87)</td>
<td>29 ± 5</td>
<td>1 month</td>
<td>24-h</td>
<td>−2</td>
<td>RCT</td>
<td>26 ± 12</td>
<td>11 ± 12</td>
<td>56%</td>
</tr>
</tbody>
</table>

SD, standard deviation; 24-h (or 20-h), automatic BP measurement during 24 hours a day (or 20 h); Clinical, BP measurement manual or electric; BMI, body mass index (kg/m²); AHI, apnea-hypopnea index; RCT, randomized controlled trial.

A summary of OAm treatment studies assessing BP parameters is given in Table 2. In 8 studies, BP of 590 OSA patients was monitored, with a mean BP decrease of 4.2 mm Hg during OAm therapy.

Endothelial Function

Although OSA patients may not show signs of cardiovascular disease, they do show early signs of atherosclerosis, such as endothelial dysfunction (ED), increase in intima thickness, increased carotis diameter and increased biomarkers of oxidative stress and inflammation.37–41 These signs are significantly correlated with OSA severity.37,39,40,42,46

Izhashi et al.47 examined oxidative stress and EF after 3 months and after 1 year of OAm therapy in a controlled study. The study group consisted of 16 patients, 12 of whom completed the 1-year evaluation. The control group consisted of 9 patients, and the study also used a reference group of 10 patients without OSA (AHI ≤ 10/h). The reactive hyperemia peripheral arterial tonometry (RH-PAT) was measured and represents EF. This value improved from 1.77 ± 0.4 to 2.1 ± 0.4 after 3 months and to 2.0 ± 0.3 after 1 year of treatment. The results under OAm therapy did not differ significantly from those of the reference group. The thiobarbituric acid-reactive substance (TBARS) also was measured, representing the oxidative stress, and was
expressed in nanomole malondialdehyde per milliliter plasma. The TBARS value decreased from 18.8 ± 6.2 to 15.8 ± 3.9 after 3 months and remained at 15.5 ± 3.2 after 1 year. There was a correlation between the change in AHI, EF, and TBARS values.

Trzepizur et al.\textsuperscript{48} examined the microvascular endothelial function (MVEF) in a study group of 12 patients and a control group of 9 patients (AHI < 15/h). MVEF was measured with laser Doppler flowmetry combined with acetylcholine (ACh) and sodium nitroprusside (SNP) iontophoresis. Cutaneous vascular conductance (CVC) was expressed in AU/mm Hg. CVC values were measured before OAm and CPAP treatment and were compared to control group values and posttreatment values. Baseline CVC did not differ between the control group and the study group before OAm treatment. CVC measurements with ACh showed a significantly higher CVC peak in the control group being 3.8 multiple of baseline conductance (MBC) in comparison to the study group for OAm treatment (2.3 MBC). Correlation analysis of the study and control groups showed that ACh-induced CVC peak was negatively correlated to AHI. CVC values of the study group increased in comparison to baseline after OAm treatment. There was a significant increase in ACh-induced CVC peak after OAm treatment. An increase in SNP-induced CVC peak was also found but was not significant.

Both studies show that EF is correlated to AHI, which emphasizes the importance of an optimal treatment of OSA patients.

**Left Ventricle**

In patients without cardiovascular diseases, OSA is associated with an elevated incidence of both diastolic and systolic dysfunction and left ventricular hypertrophy.

Hoekema et al.\textsuperscript{49} examined the left ventricle (LV) function of 28 patients with mild to moderate OSA (AHI < 20/h) before and after 2–3 months of OAm (15 patients) or CPAP (13 patients) therapy. They evaluated LV function with echocardiography and measurements of the amino-terminal fragment of the pro-brain natriuretic peptide (NT-pro-BNP). The echocardiographic values after OAm treatment were not significantly different from the values before treatment. The concentration NP, which reflects left ventricular wall stress, decreased significantly after OAm treatment; this value increased after CPAP treatment. The changes in these values suggest improved cardiac function after OAm therapy.

Less research was performed in the domain of heart function, which can be monitored by echocardiography. Only 1 study compared the left ventricle function of 15 patients before and after 2–3 months of OAm therapy.

**DISCUSSION**

In this article we have performed a systematic review of the current evidence regarding the cardiovascular benefits of oral appliance therapy in obstructive sleep apnea patients. After online database research we analyzed 11 relevant articles.

This systematic review demonstrates that the evolution of BP after OAm therapy is studied in detail. BP decreased significantly during OAm therapy in 7 of 8 studies. The two studies comparing OAm with CPAP therapy showed no significant difference in BP results during both therapies. The results during OAm therapy were in the same order of magnitude as after CPAP therapy.\textsuperscript{33,38} Phillips et al.\textsuperscript{25} explained these similar results by the greater efficacy of CPAP and the greater compliance with OAm therapy.\textsuperscript{32,37,34} A clear variability in treatment response rate between the 8 different studies, evaluating BP changes, can be seen in Table 2, with 34% as lowest and 75% as highest treatment response rate. This treatment response is not correlated with the baseline AHI and probably correlated with the decrease in BP. Thereby we assume that the benefit on the heart will be the greatest in optimal OSA treatment.

Less research was performed in the domain of heart function, which can be monitored by echocardiography. Only 1 study compared the left ventricle function of 15 patients before and after 2–3 months of OAm therapy,\textsuperscript{49} more extensive research in this topic would be interesting. Both articles studying EF show that EF is correlated to AHI, which emphasizes the importance of an optimal treatment of OSA patients.

In this systematic review, only 3 of 11 studies evaluated their patients after a treatment period longer than 3 months as seen in Table 2. The washout period, which is the period without OSA therapy to eliminate the effects of previous therapy, was not always documented. There are no absolute recommendations on how long OSA therapy should be employed to achieve maximal beneficial cardiac effects or how quickly the beneficial cardiac effects are reversed after discontinuation of the treatment. Cardiac evaluation of patients, with a washout period of at least 3 months and an OAm treatment period of 6 months to 1 year may be worth studying.

Following current recommendations OAm therapy is prescribed for a select group of OSA patients with an AHI < 20/h or in patients for whom CPAP does not work or is not tolerated.\textsuperscript{22} Given this recommendation, it would be interesting to study cardiovascular benefit in a patient group with an AHI ≥ 20/h or to make a subanalysis of this group. Secondly only 3 of 11 studies compared cardiovascular effects during OAm therapy with cardiovascular effects during CPAP therapy. Since the cardiovascular morbidity and mortality is an important feature in treating OSA, more evidence comparing these two different treatment modalities is necessary. Large scale studies have demonstrated that CPAP reduces the risk of fatal and non-fatal cardiovascular events in severe OSA.\textsuperscript{50,51} In an observational study, Anandam et al.\textsuperscript{52,53} examined the cardiovascular mortality in 570 patients with severe OSA treated with either CPAP or OAm. Untreated severe OSA was a strong predictor of cardiovascular death. Cardiovascular death rates of CPAP- and OAm-treated patients were similar (compared to each other) and both significantly lower than the untreated OSA patients. Although residual AHI for OAm-treated patients was significantly higher than CPAP-treated patients, there was no difference in cardiovascular death rate between the two groups. Some studies included in this review demonstrate that patients under OAm therapy report higher subjective compliance than CPAP therapy.\textsuperscript{25,36} Objective measurement of compliance of OAm therapy has become feasible using an incorporated sensor in the OAm.\textsuperscript{54} Consequently, compliance will become more accurately assessable and will become an important variable in the comparison between CPAP and OAm therapy outcome. Not only efficacy, but also compliance is an important factor in comparing different treatment modalities. The product of
efficacy and compliance can be formulated as the mean disease alleviation (MDA), as described by Vanderveken et al.\textsuperscript{54} MDA can be a measure for the net effectiveness of a therapy. Even if CPAP is superior to OAm in reducing AHI, in terms of efficacy the MDA values of both CPAP and OAm therapy are in the same order of magnitude due to the higher compliance to OAm.

All this could be elucidated further by studying the cardiovascular benefits between 6 and 12 months of OAm therapy, including implementation of objective compliance measurement, as well as extensive cardiovascular follow-up of patients, and in patients with more severe OSA and in comparison with CPAP treatment.

**CONCLUSION**

The results of this concise review indicate that OAm therapy provides a beneficial effect on the cardiovascular comorbidity in OSA patients. Improvement in BP, EF, and left ventricular function are proven in several independent studies. The studies comparing OAm therapy to CPAP therapy even illustrate that the reduction in BP values after both therapies might be of the same order of magnitude. This finding contrasts with the current recommendations for OSA treatment in which OAm therapy is prescribed for a select group of OSA patients with an AHI < 20/h or in patients for whom CPAP does not work or is not tolerated and calls for further research in this field.\textsuperscript{22}

**REFERENCES**


40. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ. 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. *Chest* 2003;124:1386–92.


**SUBMISSION & CORRESPONDENCE INFORMATION**

Submitted for publication June, 2014

Submitted in final revised form September, 2014

Accepted for publication October, 2014

Address correspondence to: Gilles Van Haesendonck, Faculty of Medicine and Health Sciences, University of Antwerp, Department of ENT, Head and Neck Surgery, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium; Tel: +32 3 821 33 85; Email: gvanhaesendonck@gmail.com

**DISCLOSURE STATEMENT**

This was not an industry supported study. Dr. Braem has received research support from Somnomed. Dr. Vanderveken is a co-investigator for a study supported by Inspire Medical Systems Inc., and he consults for Inspire Medical Systems Inc. and for Philips Electronics B.V. He is co-promoter of a Research Grant from SomnoMed Ltd. at Antwerp University Hospital (2013–2015). His department received support in the form of free devices for a RCT with sleep position trainer in 20 patients from Nightbalance NV, Delft, the Netherlands. The other authors have indicated no financial conflicts of interest.